This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially informed and sometimes misinformed potential consumers. Compounded ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

1. In this systematic review, glucagon-like peptide-1 receptor agonists and co-agonists were effective in inducing weight loss in overweight adults who were otherwise healthy and did not have diabetes ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including neurocognitive and ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...